Calcimedica announces upcoming presentation at digestive disease week 2024

Collaborators from cedars-sinai to present human proteomics data supporting the potential benefits of auxora™ in severe acute pancreatitis (ap) la jolla, calif., may 7, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation by a collaborator from cedars-sinai medical center at the upcoming digestive disease week (ddw) 2024 being held may 18-21 in washington, dc and virtually.
CALC Ratings Summary
CALC Quant Ranking